Trial | NCT00639756  Report issue

Title

The Effect of Allopurinol on Insulin Resistance and Blood Pressure
Phase 2 Study to Determine if Allopurinol Blocks Features of Metabolic Syndrome Induced by Fructose Ingestion

  • Phase

    Phase 2

  • Study Type

    Interventional

  • Status

    Completed No Results Posted

  • Intervention/Treatment

    allopurinol ...

  • Study Participants

    60
Studies in animals have found that allopurinol can markedly improve fructose induced metabolic syndrome. In this study we test the hypothesis that allopurinol may lower BP, reduce triglycerides, and improve metabolic parameters in subjects placed on a high fructose diet.
60 male subjects, age 40 to 65 years of age, will be placed on a 3500kcal (55% carbohydrates containing 200 g fructose) for 2 weeks. Half will receive allopurinol mg/day (randomized). At the end of 2 weeks we measure a variety of parameters including fasting glucose and insulin levels (with calculation of HOMA index), serum lipids (including triglycerides and LDL/HDL cholesterol), sitting blood pressure, serum uric acid, weight, and various other measurements (C reactive protein, adiponectin and leptin levels, and urate redox products). Primary endpoint is insulin resistance. Secondary endpoints are blood pressure, lipids, uric acid, weight.
Study Started
Jun 30
2008
Primary Completion
Aug 31
2008
Study Completion
Oct 31
2008
Last Update
Oct 13
2008
Estimate

Drug Allopurinol

Allopurinol 300 mg

Drug Placebo

Placebo given for 2 weeks

1 Other

Placebo

2 Active Comparator

Allopurinol given for 2 weeks with diet

Criteria 

Inclusion Criteria:

Males, age 40 -65 yrs

Exclusion Criteria:

None
No Results Posted